NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis $2.00 +0.01 (+0.50%) Closing price 10/1/2025 03:57 PM EasternExtended Trading$2.00 0.00 (-0.25%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adagene Stock (NASDAQ:ADAG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adagene alerts:Sign Up Key Stats Today's Range$1.97▼$2.0350-Day Range$1.65▼$2.5052-Week Range$1.33▼$3.16Volume27,204 shsAverage Volume87,545 shsMarket Capitalization$94.26 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview Adagene Inc., headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy. At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability. The immunome platform enables rapid identification of high-quality antibody candidates derived from healthy donor B cells, while the AI-driven design engine accelerates selection and engineering, aiming to streamline candidate advancement toward investigational new drug filings and clinical trials. Adagene operates research facilities in Suzhou and maintains an office in Cambridge, Massachusetts, serving global markets through strategic collaborations with leading pharmaceutical partners. The company’s leadership team is led by founder and CEO Dr. Ying Yan, whose expertise in antibody discovery and immuno-oncology has driven the development of its platform-based strategy. Under her guidance, Adagene has expanded its research capabilities and advanced multiple therapeutic candidates into the clinic.AI Generated. May Contain Errors. Read More Adagene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreADAG MarketRank™: Adagene scored higher than 50% of companies evaluated by MarketBeat, and ranked 617th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingAdagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialAdagene has a consensus price target of $7.00, representing about 250.0% upside from its current price of $2.00.Amount of Analyst CoverageAdagene has only been the subject of 3 research reports in the past 90 days.Read more about Adagene's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($0.60) to ($0.76) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.12% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently increased by 320.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.12% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently increased by 320.19%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.28 News SentimentAdagene has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adagene this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.51% of the stock of Adagene is held by institutions.Read more about Adagene's insider trading history. Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADAG Stock News HeadlinesCD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso ...October 1 at 8:20 AM | finance.yahoo.comLUCID CAPITAL MARKETS Initiates Coverage of Adagene Inc. - Depositary Receipt (ADAG) with Buy RecommendationSeptember 19, 2025 | msn.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.October 2 at 2:00 AM | The Oxford Club (Ad)Adagene initiated with a Buy at Lucid CapitalSeptember 18, 2025 | msn.comAdagene expands SAFEbody collaboration, license agreement with ExelixisSeptember 16, 2025 | msn.comAdagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug ConjugateSeptember 16, 2025 | globenewswire.comAdagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, ChinaSeptember 5, 2025 | markets.businessinsider.comAdagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, ChinaSeptember 5, 2025 | globenewswire.comSee More Headlines ADAG Stock Analysis - Frequently Asked Questions How have ADAG shares performed this year? Adagene's stock was trading at $1.99 on January 1st, 2025. Since then, ADAG stock has increased by 0.5% and is now trading at $2.00. When did Adagene IPO? Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager. How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adagene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Today10/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAG CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees260Year Founded2012Price Target and Rating Average Price Target for Adagene$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+250.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick RatioN/A Sales & Book Value Annual Sales$100 thousand Price / Sales942.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book1.75Miscellaneous Outstanding Shares47,130,000Free Float37,139,000Market Cap$94.26 million OptionableNot Optionable Beta0.74 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ADAG) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.